Government of Canada
Symbol of the Government of Canada

TCPS 2 - Chapter 3


A. General Principles
B. Departures from General Principles of Consent
C. Capacity
D. Consent Shall Be Documented


This chapter sets out the ethical requirements for consent in research involving humans. Throughout this Policy, the term  “consent ” means “free, informed and ongoing consent.” For the purpose of this Policy, “free” and “voluntary” are used interchangeably.

Respect for Persons implies that individuals who participate in research should do so voluntarily, understanding the purpose of the research, and its risks and potential benefits, as fully as reasonably possible. Where a person has the capacity to understand this information, and the ability to act on it voluntarily, the decision to participate is generally seen as an expression of autonomy. The Policy refers to the process of seeking consent from prospective participants, which may result in either agreement or refusal to participate. This process is meant to emphasize Respect for Persons. Under no circumstances may researchers proceed to conduct research with anyone who has refused to participate. Subject to exceptions set out in this Policy, consent must be obtained from participants prior to the conduct of research.

Equally, Respect for Persons implies that those who lack the capacity to decide for themselves should nevertheless have the opportunity to participate in research that may be of benefit to themselves or others. Authorized third parties acting on behalf of these individuals decide whether participation would be appropriate. For the purposes of this Policy, the term “authorized third party” (also known as “authorized third party decision makers”) refers to any person with the necessary legal authority to make decisions on behalf of an individual who lacks the capacity to consent to participate or to continue to participate in a particular research project. These decisions involve considerations of Concern for Welfare and Justice.

Certain types of research require alternate processes for seeking consent. These are also described in this chapter. Where elements of the consent process may need to be adapted to the requirements of a particular research project, the research ethics board (REB) can play an educational and consultative role in determining the appropriate process for seeking and maintaining consent.

The head of the research team, also known as the principal investigator, is responsible for ensuring that the consent process is followed. This person is also responsible for the actions of any member of the research team involved in the consent process.

In addition to this Policy, researchers are responsible for ensuring that all applicable legal and regulatory requirements with respect to consent are met. In some circumstances, researchers may have further legal obligations that may be determined in part by the nature of the research and the jurisdiction in which the research is being conducted.1

A. General Principles

Consent Shall Be Given Voluntarily

Article 3.1  (a) Consent shall be given voluntarily.

(b) Consent can be withdrawn at any time.

(c) If a participant withdraws consent, the participant can also request the withdrawal of their data or human biological materials.

Application  (a) The voluntariness of consent is important because it respects human dignity and means that individuals have chosen to participate in research according to their own values, preferences and wishes.

The approach to recruitment is an important element in assuring voluntariness. In particular, how, when and where participants are approached, and who recruits them are important elements in assuring (or undermining) voluntariness. In considering the voluntariness of consent, REBs and researchers should be cognizant of situations where undue influence, coercion or the offer of incentives may undermine the voluntariness of a participant’s consent to participate in research.

Undue Influence

Undue influence and manipulation may arise when prospective participants are recruited by individuals in a position of authority. The influence of power relationships (e.g., employers and employees, teachers and students, commanding officers and members of the military or correctional officers and prisoners) on the voluntariness of consent should be judged from the perspective of prospective participants, since the individuals being recruited may feel constrained to follow the wishes of those who have some form of control over them. This control may be physical, psychological, financial or professional, for example,and may involve offering some form of inducement or threatening some form of deprivation. In such situations, the control exerted in a power relationship may place undue pressure on the prospective participants. At the extreme, there can be no voluntariness if consent is secured by the order of authorities.

REBs and researchers should also pay particular attention to elements of trust and dependency in relationships (e.g., between physician and patient or between professor and student). These relationships can impose undue influence on the individual in the position of dependence to participate in research projects. Any relationship of dependency, even a nurturing one, may give rise to undue influence even if it is not applied overtly. There may be a greater risk of undue influence in situations of ongoing or significant dependency.

Pre-existing entitlements to care, education and other services should not be prejudiced by the decision of whether or not to participate in, or to withdraw from, a research project. Accordingly, for example, a physician should ensure that continued clinical care is not linked to research participation. Similarly, where students do not wish to participate in research studies for course credits, they should be offered a comparable alternative.


Coercion is a more extreme form of undue influence, involving a threat of harm or punishment for failure to participate. Coercion would negate the voluntariness of a decision to participate, or to remain, in a research project.


Incentives are anything offered to participants, monetary or otherwise, for participation in research (incentives differ from reimbursements and compensation for injury, which are discussed in Article 3.2[j]). Because incentives are used to encourage participation in a research project, they are an important consideration in assessing voluntariness. Where incentives are offered to participants, they should not be so large or attractive as to encourage reckless disregard of risks.This is a particular consideration in the case of healthy volunteers for the early phases of clinical trials, as discussed in Article 11.1. The offer of incentives in some contexts may be perceived by prospective participants as a way for them to gain favour or improve their situation. This may amount to undue inducement and thus negate the voluntariness of participants’ consent.

This Policy neither recommends nor discourages the use of incentives. The onus is on the researcher to justify to the REB the use of a particular model and the level of incentives. In considering the possibility of undue influence in research involving financial or other incentives, researchers and REBs should be sensitive to issues such as the economic circumstances of those in the pool of prospective participants, the age and capacity of participants, the customs and practices of the community, and the magnitude and probability of harms (see Chapter 4, Section B). Guardians and authorized third parties should not receive incentives for arranging the involvement in research of the individual they represent. However, they may accept reasonable incentives or compensation on behalf of that individual, as long as these are suitable to the circumstances.

(b) To maintain the element of voluntariness, participants shall be free to withdraw their consent to participate in the research at any time, and need not offer any reason for doing so. In some cases, however, the physical practicalities of the project may prevent the actual withdrawal of the participant partway through, for example, if the project involves only a single intervention, or if the termination of a medical research procedure may compromise the safety of the participant.

The participant should not suffer any disadvantage or reprisal for withdrawing nor should any payment due prior to the point of withdrawal be withheld. If the research project used a lump-sum incentive for participation, the participant is entitled to the entire amount.If a payment schedule is used, participants shall be paid in proportion to their participation.

(c) The consent form should set out any circumstances that do not allow withdrawal of data or human biological materials once collected. Where the terms of the research do not allow for withdrawal of their data or human biological materials, the identity of the participants shall be protected at all times during the project and after its completion. In some research projects, the withdrawal of data or human biological materials may not be feasible (e.g., when personal information has been anonymized and added to a data pool). Participants shall also be informed that it is difficult, if not impossible, to withdraw results once they have been published or otherwise disseminated.

Consent Shall Be Informed

Article 3.2  Researchers shall provide to prospective participants, or authorized third parties, full disclosure of all information necessary for making an informed decision to participate in a research project.

Application   At the commencement of any process of consent, researchers (or their qualified representatives) shall provide prospective participants with the information set out in the following list, as appropriate to the particular research project. Not all the listed elements are required for all research. However, additional information may be required in particular types of research or under particular circumstances.

If a researcher does not include some of the listed disclosure requirements, they should explain to the REB why these requirements do not apply to that particular project. It is also up to the REB to consider whether all elements listed, or additional elements, are necessary to the consent process of the research project.

The information generally required for informed consent includes:

(a) information that the individual is being invited to participate in a research project;

(b)  a statement of the research purpose in plain language, the identity of the researcher, the identity of the funder or sponsor, the expected duration and nature of participation, a description of research procedures, and an explanation of the responsibilities of the participant;

(c)  a plain language description of all reasonably foreseeable risks and potential benefits, both to the participants and in general, that may arise from research participation;

(d)  an assurance that prospective participants:

  • are under no obligation to participate; are free to withdraw at any time without prejudice to pre-existing entitlements;
  • will be given, in a timely manner throughout the course of the research project, information that is relevant to their decision to continue or withdraw from participation; and
  • will be given information on the participant’s right to request the withdrawal of data or human biological materials, including any limitations on the feasibility of that withdrawal;

(e)  information concerning the possibility of commercialization of research findings, and the presence of any real, potential or perceived conflicts of interest on the part of the researchers, their institutions or the research sponsors;   

(f)  the measures to be undertaken for dissemination of research results and whether participants will be identified directly or indirectly;

(g)  the identity and contact information of a qualified designated representative who can explain scientific or scholarly aspects of the research to participants;

(h)  the identity and contact information of the appropriate individual(s) outside the research team whom participants may contact regarding possible ethical issues in the research;

(i)  an indication of what information will be collected about participants and for what purposes;an indication of who will have access to information collected about the identity of participants, a description of how confidentiality will be protected (see Article 5.2), a description of the anticipated uses of data; and information indicating who may have a duty to disclose information collected, and to whom such disclosures could be made;

(j)  information about any payments,including incentives for participants, reimbursement for participation-related expenses and compensation for injury;

(k) a statement to the effect that, by consenting, participants have not waived any rights to legal recourse in the event of research-related harm; and

(l)  in clinical trials, information on stopping rules and when researchers may remove participants from trial.

For consent to be informed, prospective participants shall be given adequate time and opportunity to assimilate the information provided, pose any questions they may have, and discuss and consider whether they will participate. The time required for this initial phase of the consent process will depend on such factors as the magnitude and probability of harms, the complexity of the information conveyed, and the setting where the information is given.

The key to informed consent is that prospective participants understand the information being conveyed to them by researchers. Researchers and REBs should consider how best to convey that information to facilitate understanding. For example, written documentation may be supplemented with audio and/or visual aids, or accompanied by video presentations.

When language barriers necessitate the assistance of an intermediary for communication between the research team and participants, the researcher should select an intermediary who has the necessary language skills to ensure effective communication (see Article 4.1).The involvement of such intermediaries may raise confidentiality issues (see Article 5.2).

Paragraphs (a) to (c) require researchers to clearly explain the nature and goals of the research, and other essential information, in a manner that best promotes understanding on the part of prospective participants.

Paragraph (b) requires the disclosure of those who support a particular research project, through funding or sponsorship. It is unethical for researchers to engage in clandestine activities for intelligence, police or military purposes under the guise of research.

Paragraph (c) requires researchers to consider all reasonably foreseeable risks that may result from participation. When research is conducted about an organization or a community, researchers should inform prospective participants within that organization or community of the extent to which the organization or community is collaborating with the research, as well as any risk this collaboration may pose to the participant.

Paragraph (d) helps to ensure the effectiveness of Article 3.1 – that a prospective participant’s choice to participate is voluntary. Paragraph (d) also supports the requirement that the consent process continue throughout the research.

Paragraph (e) aims at managing real, potential or perceived conflicts of interests. Researchers should separate, to the greatest extent possible, their role as researcher from their other roles as therapists, caregivers, teachers, advisors, consultants, supervisors, employers or the like. If a researcher is acting in dual roles, this fact must always be disclosed to the participant. Conflict of interest matters are further elaborated in Chapter 7.

Paragraph (f) requires that researchers provide a reasonable explanation of the measures they will undertake to publish and otherwise disseminate the results of the research – to the extent that it is feasible, and in a manner that is appropriate. Beyond the ethical obligation to disseminate results in such areas as clinical trials, this requirement is grounded on the reasonable expectation of participants that results will be published or otherwise disseminated in the public domain to advance societal knowledge (addressed further in Articles 11.3 and 11.12). With respect to research involving Aboriginal peoples and disclosure of information, see Chapter 9.

Paragraph (h) acknowledges that some institutions may decide either to name an ombudsman for participants, or designate a resource person to handle queries, receive complaints, and transmit those complaints to the REB. This is a matter for institutions to determine.

Paragraph (i) touches on issues of privacy and confidentiality, secondary use of data, and the possibility of compelled disclosure by the researcher to third parties for administrative and/or legal purposes. These issues are addressed in further detail in Chapter 5 and, in particular, Article 5.2.

Paragraph (j) ensures that participants are informed of the payments they will receive (if any) for their participation. Reimbursement for participation-related expenses is intended to ensure that participants are not put at a direct or indirect financial disadvantage for the time and inconvenience of participation in research. Direct expenses are costs incurred because of research participation (e.g., paying for transportation to, or parking at, the research site) while indirect expenses refer to losses that arise from participation (e.g., taking unpaid leave from work). Participants should also be informed about any compensation they may be entitled to for research-related injuries.

Paragraph (l) is intended to inform the prospective participant in clinical trials of circumstances under which the researcher may end the participant’s involvement in a research project. Clinical trials have stopping rules: statistically significant end points and safety considerations determined in advance, which, once reached, dictate that the trial must be terminated. As well, researchers may remove participants who are not following the procedures of the clinical trial or for safety reasons (see Article 11.7).

Consent Shall Be an Ongoing Process

Article 3.3  Consent shall be maintained throughout the research project. Researchers have an ongoing duty to provide participants with all information relevant to their ongoing consent to participate in the research.

Application  Consent encompasses a process that begins with the initial contact (e.g., recruitment) and carries through to the end of participants’ involvement in the project. Throughout the process, researchers have an ongoing duty to provide participants and REBs with all information relevant to participants’ ongoing consent to participate in the research. The researcher has an ongoing ethical and legal obligation to bring to participants’ attention any changes to the research project that may affect them. These changes may have ethical implications, or may be germane to their decision to continue research participation, or may be relevant to the particular circumstances of individual participants. In particular, researchers shall disclose changes to the risks or potential benefits of the research. This gives participants the opportunity to reconsider the basis for their consent in light of the new information.

In the case of children who begin participation in a project on the basis of consent from an authorized third party, the researcher must seek their autonomous consent if they reach the age of majority during the research, in order for their participation to continue.

Incidental Findings

Article 3.4  Researchers have an obligation to disclose to the participant any material incidental findings discovered in the course of research.      

Application  “Incidental findings” is a term that describes unanticipated discoveries made in the course of research but that are outside the scope of the research. Material incidental findings are findings that have been interpreted as having significant welfare implications for the participant, whether health-related, psychological or social. If, in the course of research, material incidental findings are discovered, researchers have an obligation to inform the participant.

In some areas of research, such as medical and genetic research, there is a greater likelihood of material incidental findings. When material incidental findings are likely, researchers should develop a plan indicating how they will disclose such findings to participants, and submit this plan to the REB. If there is uncertainty as to whether a research project warrants such a plan, researchers and REBs can make this determination on a case-by-case basis.

If researchers are unsure of how to interpret findings or uncertain whether findings are material, they should consult with colleagues or refer to standards in the discipline. If researchers are unsure of the most appropriate method for disclosing material incidental findings to participants, they should consult with their REB or with colleagues. Researchers should exercise caution in disclosing incidental findings that may cause needless concern to participants. When necessary, researchers should direct participants to a qualified professional to discuss the possible implications of the incidental findings for their welfare. In some cases, incidental findings may trigger legal reporting obligations and researchers should be aware of these obligations (see Article 5.1).

Consent Shall Precede Collection of, or Access to, Research Data

Article 3.5  Research shall begin only after the participants, or their authorized third parties, have provided their consent.

Application  In keeping with the principle of Respect for Persons, participants shall provide their consent prior to engaging in research. This is the clearest demonstration that their participation is based on consideration of the risks and potential benefits of the research project, and other principles in this Policy.

There are exceptions to this general ethical requirement, however, set out in Articles 3.7 and 3.8.

This article does not apply to conversations that researchers may have with prospective participants as part of the development of the design of their research. These preliminary conversations – which may include negotiations concerning the terms on which a researcher may engage with a particular community or group – do not in themselves constitute research, and therefore do not require consent (see Chapter 2, Article 6.11, Articles 9.3 to 9.6, and Article 10.1).

Critical Inquiry

Article 3.6 Permission is not required from an organization in order to conduct research on that organization. If a researcher engages the participation of members of an organization without the organization’s permission, the researcher shall inform participants of any foreseeable risk that may be posed by their participation.

Application Research in the form of critical inquiry, that is, the analysis of social structures or activities, public policies, or other social phenomena, requires an adjustment in the assessment of consent. Where the goal of the research is to adopt a critical perspective with respect to an institution, organization or other entity, the fact that the object of the research may not endorse the research project should not be a bar to the research receiving ethics approval. Where social sciences or humanities researchers seek knowledge that critiques or challenges the policies and practices of institutions, governments, interest groups or corporations, researchers do not need to seek the organization’s permission to proceed with the proposed research. If institutional approval were required, it is unlikely that research could be conducted effectively on such matters as institutional sexual abuse or a government’s silencing of dissident scientists. Important knowledge and insights from research would be forgone. Specific requirements pertain to Aboriginal organizations, which are discussed in detail in Articles 9.4 to 9.8.

REBs should not prohibit research simply because the research is unpopular or looked upon with disfavour by a community or organization, in Canada or abroad. Similarly, REBs should not veto research on the grounds that the government in place or its agents have not given approval for the research project, or have expressed a dislike for the researchers.

However, individuals who are approached to participate in a research project about their organization should be fully informed about the views of the organization regarding the research, if these are known. Researchers shall inform participants when the permission of the organization has not been obtained. Researchers engaging in critical inquiry need to be attentive to risks, both of stigmatization or breach of privacy, to those who participate in research about their organization. In particular, prospective participants should be fully informed of the possible consequences of participation.

REBs should, however, legitimately concern themselves with the welfare of participants and the security of research materials in such circumstances. When participants are vulnerable to risks from third parties (e.g., authoritarian regimes, gang leaders, employers) on account of their involvement in research, researchers should ensure that copies of field materials are kept in secure locations. When sharing research materials such as consent forms or transcripts of field notes with participants, researchers must honour their commitment to protect the anonymity and confidentiality of participants to ensure that their human rights, and the ethical principles set out in this Policy, are not compromised. In general, regardless of where the researchers conduct their research, researchers and REBs should concern themselves with safeguarding information while it is in transit (see Articles 5.1 to 5.4).

REBs should also be aware that some research, involving critical assessments of public, political or corporate institutions and associated public figures, for example, may be legitimately critical and/or opposed to the welfare of those individuals in a position of power, and may cause them some harm. There may be a compelling public interest in this research. Therefore, it should not be blocked through the use of risk-benefit analysis. Such research should be carried out according to the professional standards of the relevant discipline(s) or field(s) of research. Where an individual in a position of power is invited to be interviewed or gives access to private papers and thus becomes a participant as defined by this Policy, Article 3.2 applies (see also Article 3.12, Article 9.7 and Article 10.2). In such cases, the balance of risks to those who are the object of the research is mainly considered along with the potential benefit of new knowledge to society and the indirect benefits to the population affected by the public, political or corporate institutions to which the participant belongs.

B.  Departures from General Principles of Consent

Alteration of Consent in Minimal Risk Research

Article 3.7  The REB may approve research without requiring that the researcher obtain the participant’s consent in accordance with Articles 3.1 to 3.5 where the REB is satisfied, and documents, that all of the following apply:

(a) the research involves no more than minimal risk to the participants;

(b) the lack of the participant’s consent is unlikely to adversely affect the welfare of the participant;

(c) it is impossible or impracticable to carry out the research and to answer the research question properly, given the research design, if the prior consent of the participant is required;

(d) whenever possible and appropriate, after participation, or at a later time during the study, participants will be debriefed and provided with additional pertinent information in accordance with Articles 3.2 and 3.4, at which point they will have the opportunity to refuse consent in accordance with Article 3.1; and

(e) the research does not involve a therapeutic intervention, or other clinical or diagnostic interventions.

Application  In the circumstances described under Article 3.7, the nature of the research may justify a limited or temporary departure from the general requirement for consent prior to participation in research. “Impracticable” refers to undue hardship or onerousness that jeopardizes the conduct of the research. It is the responsibility of researchers to justify the need for such a departure. It is the responsibility of REBs, however, to understand that certain research methods necessitate a different approach to consent, and to exercise judgment on whether the need for the research justifies a limited or temporary exception to the general requirements in a particular case (Article 3.7 does not address the exception to the requirement of consent for secondary use of identifiable information; this topic is addressed in Article 5.5).

It should be noted that in cases of randomization and blinding in clinical trials, neither the participants nor the researchers know which treatment arm the participant will be receiving before the research commences. As long as participants are informed of the probability of their assignment to each arm of the trial, this random and blind assignment does not constitute a waiver or alteration of consent.

Research Involving Partial Disclosure or Deception

Some social science research, particularly in psychology, seeks to learn about human responses to situations that have been created experimentally. Some types of research can be carried out only if the participants do not know the true purpose of the research in advance. For example, some social science research that critically probes the inner workings of publicly accountable institutions might never be conducted without the limited use of partial disclosure. In some research that uses partial disclosure or deception, participants may not know that they are part of a research project until it is over, or they may be asked to perform a task and told about only one of several elements the researchers are observing. Research employing deception can involve a number of techniques, such as giving participants false information about themselves, events, social conditions and/or the purpose of the research. For such techniques to fall within the exception to the general requirement of full disclosure for consent, the research must meet the requirements of Article 3.7.

Where partial disclosure or deception has been used, debriefing is an important mechanism in maintaining the participant’s trust in the research community. The debriefing referred to in Article 3.7(d) should be proportionate to the sensitivity of the issue. Often, debriefing can be a simple and straightforward candid disclosure. In sensitive cases, researchers should also provide a full explanation of why participants were temporarily led to believe that the research, or some aspect of it, had a different purpose, or why participants received less than full disclosure. The researchers should give details about the importance of the research, the necessity of having to use partial disclosure or deception, and express their concern about the welfare of the participants. They should seek to remove any misconceptions that may have arisen and to re-establish any trust that might have been lost, by explaining why these research procedures were necessary to obtain scientifically valid findings.

Immediate, full debriefing of all individuals who have contributed data may not be feasible in all cases. In studies with data collection over a longer term, debriefing may have to be deferred until the end of the project. In some cases – for example, in research involving children – it may be more appropriate to debrief the parents, guardians or authorized third parties rather than the participants themselves. In other cases, it may be more appropriate to debrief the entire family or community. When debriefing, researchers should be alert and sensitive to participants’ needs, feelings, reactions and concerns.

In studies involving partial disclosure or deception in which an alteration to the requirement for prior consent has been allowed, participants must nevertheless be able to indicate their consent or their refusal at the conclusion of the project, following debriefing. In cases where participants express concerns about their participation in a project, the researcher may give participants the option of removing their data from the project. Where the terms of the research proposal do not permit the participants to withdraw their data, in the absence of the consent of the participant, the identity of the participants shall be protected at all times during and following completion of the project. Participants who express concern about the conduct of the project at the time of debriefing, or who contest the limits imposed on withdrawing their data, should be given the contact information for the REB that approved the research. Researchers must report to the REB concerns about the conduct of the project raised by participants at the time of debriefing.

Consent for Research in Individual Medical Emergencies

This section addresses the exception to consent in situations where an individual who requires urgent medical care is unable to provide consent for research due to loss of consciousness or capacity – and the delay to seek authorized third party consent could seriously compromise that individual’s health. Certain types of medical emergency practices can be evaluated only when they occur, hence the need for this exception.

This section is to be distinguished, however, from situations where there is a publicly declared emergency (such as the SARS crisis or a major flood) that disrupts the ordinary system for obtaining REB approval for research. For guidance on research ethics review during a publicly declared emergency, see Articles 6.21 and 6.22.

Article 3.8 Subject to all applicable legal and regulatory requirements, research involving medical emergencies shall be conducted only if it addresses the emergency needs of the individuals involved, and then only in accordance with criteria established in advance of such research by the REB. The REB may allow research that involves medical emergencies to be carried out without the consent of participants, or of their authorized third party, if all of the following apply:

(a) a serious threat to the prospective participant requires immediate intervention;

(b) either no standard efficacious care exists or the research offers a realistic possibility of direct benefit to the participant in comparison with standard care;

(c) either the risk is not greater than that involved in standard efficacious care, or it is clearly justified by the prospect for direct benefits to the participant;

(d) the prospective participant is unconscious or lacks capacity to understand the risks, methods and purposes of the research project;

(e) third party authorization cannot be secured in sufficient time, despite diligent and documented efforts to do so; and

(f) no relevant prior directive by the participant is known to exist.

When a previously incapacitated participant regains capacity, or when an authorized third party is found, consent shall be sought promptly for continuation in the project, and for subsequent examinations or tests related to the research project.

Application For purposes of studying potential improvement in the treatment of life-threatening conditions, Article 3.8 outlines an exception (in addition to that in Article 3.7) to the general obligation of seeking consent from those participating in research.

It is the responsibility of researchers to justify to the REB the need for this exception. The underlying assumption of Article 3.8 is that participants could not receive any direct benefits of the research without setting aside the need for the researcher to seek the prior consent of participants, or of their authorized third party. Article 3.8 indicates that research in emergency medicine must be reviewed by the REB, be restricted to the emergency needs of the participants, and be conducted under criteria designated by the REB.

It is unethical to expose participants to any additional risk without their consent if standard efficacious care exists, unless it can clearly be shown that there is a realistic possibility of meaningful improvement of the participant’s condition. Accordingly, paragraphs (b) and (c) of Article 3.8 indicate that researchers and REBs must assess the risks and potential benefits of proposed research against existing standard efficacious care.

To respect the autonomy of the participant, Article 3.8(e) requires researchers to undertake diligent efforts to contact authorized third parties, if reasonably feasible, and to document such efforts for the benefit of both the participant and the continuing ethics review functions of the REB. The article also requires that participants who regain capacity be promptly afforded the opportunity to consent to their continued participation. Concern for the patient’s welfare is paramount and should be informed by ethical and professional judgment.

Because their incapacity to exercise consent makes them vulnerable, prospective participants for emergency research are owed special ethical obligations and protection commensurate with the risks involved. Their welfare should be protected by additional safeguards, where feasible and appropriate. These might include:additional scientific, medical or REB consultation; procedures to identify prospective participants in advance so that consent may be sought prior to the occurrence of the emergency situation; consultation with former and prospective participants; and special monitoring procedures to be followed by data safety and monitoring boards.

C. Capacity

Capacity refers to the ability of prospective or actual participants to understand relevant information presented about a research project, and to appreciate the potential consequences of their decision to participate or not participate. This ability may vary according to the complexity of the choice being made, the circumstances surrounding the decision, or the point in time at which consent is sought. The determination of capacity to participate in research, then, is not a static determination. It is a process that may change over time, depending on the nature of the decision the prospective participant needs to make, and on any changes in the participant’s condition. Assessing capacity is a question of determining, at a particular point in time, whether a participant (or prospective participant) sufficiently understands the nature of a particular research project, and the risks, consequences and potential benefits associated with it.

One may therefore have diminished capacity but still be able to decide whether to participate in certain types of research. Researchers should be aware of all applicable legal and regulatory requirements with respect to capacity. These may vary among jurisdictions. Authorized third parties who are asked to make a consent decision on behalf of a prospective participant should also be aware of their legal responsibilities.

In keeping with the principle of Justice, those who lack the capacity to consent on their own behalf must neither be unfairly excluded from the potential benefits of research participation, nor may their lack of capacity to consent be used to inappropriately include them in research. REBs and researchers should be aware of these ethical considerations and seek to find a balance between them for the benefit of prospective participants who lack capacity to consent (see Chapter 4).

As indicated in Chapter 1, Respect for Persons and Concern for Welfare entails particular ethical obligations to individuals in vulnerable circumstances. Such obligations often translate into special procedures to promote and protect their interests. This may include the development of consent materials that are appropriate to the cognitive and communication abilities of prospective participants. Articles 3.9, 3.10 and 3.11 describe special procedures for research involving individuals who lack the capacity to consent on their own behalf.

Article 3.9  For research involving individuals who lack the capacity, either permanently or temporarily, to decide for themselves whether to participate, the REB shall ensure that, as a minimum, the following conditions are met:

(a) the researcher involves participants who lack the capacity to consent on their own behalf to the greatest extent possible in the decision-making process;

(b) the researcher seeks and maintains consent from authorized third parties in accordance with the best interests of the persons concerned;

(c) the authorized third party is not the researcher or any other member of the research team;

(d) the researcher demonstrates that the research is being carried out for the participant’s direct benefit, or for the benefit of other persons in the same category. If the research does not have the potential for direct benefit to the participant but only for the benefit of the other persons in the same category, the researcher shall demonstrate that the research will expose the participant to only a minimal risk and minimal burden, and demonstrate how the participant’s welfare will be protected throughout the participation in research; and

(e) when authorization for participation was granted by an authorized third party, and a participant acquires or regains capacity during the course of the research, the researcher shall promptly seek the participant’s consent as a condition of continuing participation.

Application  The decision of authorized third parties should be based on their knowledge of the prospective participants, and on consideration of the prospective participants’ welfare. The third parties should not be in a position of conflict of interest when making their decision.

Article 3.9 outlines other safeguards to protect those who lack the capacity to consent to participate in research. The article details several considerations relevant to the use of third party authorization. Beyond the legal and regulatory requirements for seeking consent from authorized third parties, family members and friends may also provide information to the authorized third party about the interests and previous wishes of prospective participants. An authorized third party should take into account any research directives given in accordance with Article 3.11.

Article 3.10 Where an authorized third party has consented on behalf of an individual who lacks legal capacity, but that person has some ability to understand the significance of the research, the researcher shall ascertain the wishes of that individual with respect to participation. Prospective participants’ dissent will preclude their participation.

Application  Many individuals who lack legal capacity to make decisions may still be able to express their wishes in a meaningful way, even if such expression may not fulfil all of the requirements for consent. Prospective participants may be capable of verbally or physically assenting to, or dissenting from, participation in research. Those who may be capable of assent or dissent include:

(a) those whose capacity is in the process of development, such as children whose capacity for judgment and self-direction is maturing;

(b) those who once were capable of making an autonomous decision regarding consent but whose capacity is diminishing or fluctuating; and

(c) those whose capacity remains only partially developed, such as those living with permanent cognitive impairment.

While their assent would not be sufficient to permit them to participate in the absence of consent by an authorized third party, their expression of dissent or signs suggesting they do not wish to participate must be respected.

Research Directives

Although advance directives for treatment are recognized as a legitimate tool in health care, the use of directives in the context of research is not well developed and they have no legal status. For the purposes of this Policy, research directives should be understood to express an individual’s preferences for participation in future research in the event that the individual loses capacity. Research directives are written instructions to be used by the authorized third party as information about a prospective participant’s preferences when the third party is asked to provide substitute consent.

The efficacy of research directives is unknown and their legal status has not yet been recognized or tested. Research directives, nevertheless, are congruent with this Policy’s core principle of Respect for Persons. The use of research directives respects the right of individuals to express their preference regarding participation in research and respects privacy by allowing individuals to control information about themselves and materials from their bodies. Authorized third parties should consult with an individual’s research directive when deciding whether to consent to participation in research on behalf of that individual.

Article 3.11  Where individuals have signed a research directive indicating their preferences about future participation in research in the event that they lose capacity or upon death, researchers and authorized third parties should be guided by these directives during the consent process.

Application  Research directives allow individuals with capacity to express preferences about their future participation in research should they ever lose capacity. Researchers and authorized third parties should take these directives into account during the consent process, but only if the individual who provided the research directive lacks capacity at the time the research is initiated. Research directives may also be used for participants who have capacity when research is initiated but lose capacity during research.

Research directives are useful to individuals who are already participating in research as well as those who are not participating but may wish to participate in research at a later date.They give individuals a range of options regarding future participation in research. The use of research directives is particularly relevant for research involving participants with diminishing capacity, fluctuating capacity or degenerative conditions, and research that collects information or human biological materials.

The use of research directives does not alter the requirements for consent as articulated by the provisions of this Policy. In particular, in accordance with Article 3.9, researchers are required to seek the consent of authorized third parties before individuals who lack capacity can participate in research. If an individual regains capacity, the researcher should promptly seek the consent of the individual as a condition of continuing participation.

Researchers, institutions and organizations may suggest the use of research directives in order to give participants an opportunity to express preferences about the use of information or human biological material that has already been collected. Researchers who collect information or human biological materials for a specific research project may anticipate subsequent research uses. Some types of research initiatives (e.g., the creation of large databases sometimes known as research platforms) involve long-term retention and use of information or human biological materials for research purposes (e.g., longitudinal studies that involve biobanking). When data for these platforms are initially collected, it is not typically possible to specify every research that could be carried out using the participants’ information or human biological materials. Research directives may be used in these contexts to give participants the opportunity to express their preferences about future research should they lose capacity (see Article 5.5[d] for expression of preferences in the context of secondary use of data).

In long-term projects, research directives may be used to allow participants to make choices about other aspects of research participation. For example, participants could specify preferences about receiving findings, or allowing the continued use of their information or samples in the event that they lose capacity, or after they die.

Individuals can also use research directives to express preferences concerning participation in future research. For example, individuals in an early stage of cognitive impairment may use a research directive to express their preferences for future participation in research that, due to diminishing capacity, they would not otherwise be able to consent to on their own. They also allow existing participants to express their preference to continue to participate in research should they lose capacity. Research directives should be as specific as possible, and in the event of ambiguity or imprecision, should be interpreted narrowly. Individuals should be encouraged to periodically update their research directives and, if possible, construct directives in contemplation of specific types of research interventions. Research directives should be written, dated and witnessed, and include a declaration about the capacity of the individual at the time the directive was made.

D. Consent Shall Be Documented

Article 3.12 Evidence of consent shall be contained either in a signed consent form or in documentation by the researcher of another appropriate means of consent.

Application  Written consent in a signed statement from the participant is a common means of demonstrating consent, and in some instances, is mandatory (e.g., Health Canada regulations under the Food and Drugs Act, the Civil Code of Québec). However, there are other means of providing consent that are equally ethically acceptable. In some types of research, and for some groups or individuals, written signed consent may be perceived as an attempt to legalize or formalize the consent process and therefore may be interpreted by the participant as a lack of trust on the part of the researcher. In these cases, oral consent, a verbal agreement or a handshake may be required, rather than signing a consent form. In some cultures, the giving and receiving of gifts symbolizes the establishment of a relationship comparable to consent.

Where consent is not documented in a signed consent form, researchers may use a range of consent procedures, including oral consent, field notes and other strategies, for documenting the consent process. Consent may also be demonstrated solely by the actions of the participant (e.g., through the return of a completed questionnaire). Where there are valid reasons for not recording consent in writing, the procedures used to seek consent must be documented (see Article 10.2).

Whether or not a consent form is signed, it may be advisable to leave a written statement of the information conveyed in the consent process with the participant. For participants, it is evidence that they have agreed to participate in a particular research project. It may serve as a reminder to participants of the terms of the research project. It may also facilitate the ability of participants to consider and reconsider their involvement as the research proceeds. However, researchers should not leave any documentation with participants if it may compromise their safety or confidentiality. Additionally, in some cases it may not be appropriate to leave a written statement, such as in cultural settings where such written documentation is contrary to prevailing norms.


[1] For example, see Article 21 of the Civil Code of Québec, which sets conditions for the conduct of research involving minors or adults who lack the capacity to consent. [Back]

< Contents | Next >